Sept 15 2006 Biotech Daily Market Report
September 15th 2006 03:49
ASX, BIOTECHS DOWN:
LIVING CELL UP 19%, CELLESTIS DOWN 7%
THE MARKETLIVING CELL UP 19%, CELLESTIS DOWN 7%
The Australian stock market fell 0.63 percent on Friday September 15, 2006, with the All Ordinaries down 31.8 points to 4,997.2 points. Thirteen of the Biotech Daily Top 40 stocks were up, 18 stocks fell, six traded unchanged and three were untraded. Seven of the Top 20 rose and 10 fell, while six of the Second 20 rose and eight stocks fell.
Living Cell was best, up 3.5 cents or 18.92 percent to 22 cents with 176,000 shares traded, while Novogen climbed 39 cents or 15.73 percent to $2.87 with 1.6 million shares traded. Mesoblast and Portland were up more than three percent; Avexa and Proteome climbed more than two percent; with Chemgenex, Clinical Cell, Prana and Psivida up more than one percent.
Cellestis led the falls, down 22 cents or 7.05 percent to $2.90, followed by Starpharma down three cents or 6.52 percent to 43 cents and Phylogica down 2.5 cents or 5.88 percent to 40 cents. Acrux, Evogenix, Genetic technologies and Polartechnics fell more than four percent; Agenix lost 3.33 percent; Biosignal, Cytopia, Optiscan and Ventracor fell more than two percent; with CSL, Metabolic, Phosphagenics, Prima and Progen down more than one percent.
TODAY'S STORIES
* $25m RIGHTS FOR CSL’S DR BRIAN MCNAMEE, TONY CIPA
* RESONANCE RAISES $2m
* BIO-MELBOURNE RISK MANAGEMENT WORKSHOP ‘SOLD OUT’
* PSIVIDA RENEGOTIATES $15m NOTE TERMS
* RITRACT CEO BILL NICKLIN PROMOTED TO M-D
* HOSPIRA HAS 75% OF BRESAGEN
To view those stories readers need to subscribe directly to Biotech Daily.
See details at www.biotechdaily.com.au
| 36 |
| Vote |
Add To: 
subscribe to this blog